Get to know our clinical trials
Clinical trial of ro7122290, a 4-1bb (cd137l) ligand directed against fibroblast activation protein A (fap), in combination with cibisatamab, in participants with metastatic colorectal adenocarcinoma.
Codirector
Immunology and Immunotherapy Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona
Technical Summary
- AN OPEN-LABEL, MULTICENTER PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7122290, A 4-1BB (CD137L) LIGAND DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN (FAP), IN COMBINATION WITH CIBISATAMAB, WITH PRETREATMENT WITH OBINUTUZUMAB, IN PARTICIPANTS WITH METASTATIC COLORECTAL ADENOCARCINOMA WITH MICROSATELLITE STABILITY AND HIGH CEACAM5 EXPRESSION TREATED PREVIOUSLY. IMMUNOTHERAPY
- Code EudraCT: 2020-003328-17
- Protocol number: BP42675
- Promoter: Roche Farma, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.